Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 477 clinical trials
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Triple Negative Breast Cancer

This is an open-label, multi-center, non-randomized, Phase 1b/2 study to assess the safety and efficacy of fruquintinib in combination with tislelizumab in patients with advanced, refractory TNBC. This study will be conducted in 2 parts; a safety lead-in phase (Part 1) and a dose expansion phase (Part 2). The safety …

erbb2
cish
triple negative breast cancer
measurable disease
immunohistochemistry
  • 0 views
  • 20 Jul, 2021
  • 3 locations
Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer

The goal of this clinical trial is to evaluate therapeutic efficacy and safety of Chidamide combined with Cisplatin for relapsed or metastatic triple-negative breast cancer.

  • 0 views
  • 04 May, 2022
  • 1 location
Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Triple-negative breast cancer constitutes 15-20% of cases of breast cancer and is defined by the absence of estrogen receptors, progesterone receptors, and overexpression or gene amplification

erbb2
triple negative breast cancer
paclitaxel
immunohistochemistry
HER2
  • 0 views
  • 05 May, 2022
  • 1 location
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

, locally advanced or metastatic triple-negative breast cancer (TNBC) who received at least 2 prior treatments, at least 1 in the metastatic setting.

erbb2
taxane
BRCA1
triple negative breast cancer
HER2
  • 0 views
  • 16 May, 2022
  • 20 locations
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer (Pembro/IORT)

Assess response to pembrolizumab in both primary tumor, normal breast stroma, circulating lymphocytes and serum exosomes in treatment naive triple negative breast cancer (TNBC) patients.

erbb2
pembrolizumab
mk-3475
breast carcinoma
estrogen receptor
  • 40 views
  • 27 Jan, 2022
  • 1 location
Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer (ALICE)

triple-negative breast cancer. Atezolizumab, pegylated liposomal doxorubicin and cyclophosphamide are the Investigational Medicinal Products (IMPs).

erbb2
triple-negative breast cancer
measurable disease
breast cancer
immunohistochemistry
  • 392 views
  • 29 Jan, 2022
  • 5 locations
Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer

Glucose starvation and metformin have synergistic antitumor effects that are mediated through the concomitant inhibition of glycolysis and mitochondrial oxidative phosphorylation. The BREAKFAST trial will evaluate the antitumor activity of combining cyclic fasting-mimicking diet (FMD), which reproduces the in vitro effects of glucose starvation, plus/minus metformin with standard preperative anthracycline-taxane …

erbb2
taxane
gilbert's syndrome
potassium
bilateral oophorectomy
  • 33 views
  • 25 Jan, 2021
  • 1 location
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

This study will evaluate the efficacy and safety of antharcycline-based adjuvant chemotherapy compared with observation in triple negative breast cancer (TNBC) patients with residual invasive

erbb2
taxane
adenocarcinoma
triple negative breast cancer
epirubicin
  • 35 views
  • 25 Jan, 2021
  • 1 location
Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer

The primary objective of this study is to compare progression-free survival (PFS) of patients with metastatic triple-negative breast cancer randomised to treatment with standard chemotherapy

erbb2
progesterone receptor
carboplatin
ductal carcinoma
measurable disease
  • 0 views
  • 13 Nov, 2021
  • 1 location
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

This is a single arm, window of opportunity study in which participants with previously untreated triple negative breast cancers (TNBC) who are candidates for potentially curative surgery will receive one 21-day cycle of therapy prior to surgery, consisting of lenvatinib 12 mg daily, days 1 through 14, and pembrolizumab 200 …

erbb2
gilbert's syndrome
pembrolizumab
breast carcinoma
estrogen receptor
  • 0 views
  • 10 Jun, 2021
  • 1 location